

Cardiac electrical changes during co-administration of artemether-lumefantrine and atazanavir/ritonavir in HIV-infected Nigerian adults

ABSTRACT

Background: Malaria and HIV infections are both major public health problems in Africa with significant morbidity and mortality. Atazanavir and artemether-lumefantrine are used in the treatment of HIV and Malaria respectively which are co-administered when there is co-infection with both diseases. Both drugs are known to independently cause cardiac electrical abnormalities. In addition, atazanavir inhibits CYP3A4 which is the enzyme that metabolize lumefantrine with potential for increased cardiac electrical abnormalities. We therefore assessed the cardiac electrical activities during co-administration of atazanavir and artemether-lumefantrine.

Method: Forty-one consecutive HIV-infected adults attending the Anti-retroviral therapy clinic in a Nigeria General hospital were enrolled into the study using convenience sampling technique. Study participants had electrocardiographic tracings done before (day 0) and after treatment with artemether/lumefantrine (days 3 and 7).

Result: There was an increase in the mean heart rate from day 1 through day 7 but the mean heart rates were within normal limits. In contrast, there was a progressive decline in the mean PR interval from day 0 through day 7 which was not statistically significant. There was also a significant increase in corrected QT interval (QTc) between day 0 and day 3 and day 0 and day 7. Though the value of the mean QTc on day 3 (414.83 ± 34.88 ms) and day 7 (411.41 ± 22.63 ms) remained within normal limit, 5% (2) of the participant had prolonged QTc.

Conclusion: The results of this study suggested that there may be potential drug-drug interaction resulting from the co-administration of atazanavir based antiretroviral drug and artemether-lumefantrine especially in the prolongation of QTc interval

Keywords: Cardiac, co-administration, Atazanavir, Lumefantrine, QTc interval

INTRODUCTION

Malaria and HIV infection are both major public health problems in Africa in general and Nigeria in particular. Most Nigerians are at risk of malaria with about 100 million cases while HIV affects up to 3.4 million people accounting for a prevalence of 3.1%.¹ Both are major causes of morbidity and mortality with both topping the list of causes of death in Nigeria.² Studies have shown an increase in incidence of malaria in people living with HIV/AIDS (PLWHA) especially those with Low CD4 count.^{3,4} Intercurrent infection with Malaria in PLWHA decreases productivity and quality of life of patients. It may cause anorexia and vomiting and it accounts for missed doses of highly active anti retroviral therapy (HAARTs) as well as missed clinic appointment. There is also evidence to suggest a transient rise in viral load in PLWHA with intercurrent malaria infection.⁵

Currently, Nigeria ranks second only to South Africa in the population of HIV positive individuals. Malaria in PLWHA will be common. In an effort to increase cure rates and reduce emergence of resistant micro-organisms for both malaria and HIV, combination therapy has been adopted as gold standards. (WHO 2001 –Combination Rx for malaria, --- HIV reference)

In view of the foregoing, intercurrent infection with and this comes with a lot of clinical, laboratory and pharmacologic impact. Indeed

In Nigeria, the recommendations for HAART include two nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). Atazanavir/ritonavir (ATV/r) is an oral fixed-dose combination tablet of ATV (a Protease inhibitor) with low dose ritonavir, a pharmacoenhancer that significantly increases atazanavir plasma concentrations by cytochrome P450 3A4 (CYP3A4) inhibition.⁶ On the other hand, artemisinin-based combination therapy with a preference for artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) in that order is the recommended treatment for malaria. (FMOH 2005, 2011) Co-administration of atazanavir/ritonavir and artemether/lumefantrine could lead to drug-drug interaction.

Atazanavir is known to cause atrioventricular block, prolonged QT interval and Torsade des pointe.^{7,8} Lumefantrine may also cause prolongation of QT interval. However, Atazanavir is both a substrate and inhibitor of the enzyme CYP3A4 while lumefantrine is a

substrate of the enzyme.⁶ It is thus rational to expect that co-administration of the two drugs may increase the serum concentration of lumefantrine and the potential for toxicity.

This study looked at cardiac electrical abnormalities which may result from the drug-drug interaction in HIV positive patients on atazanavir taking artemether/lumefantrine combination.

UNDER PEER REVIEW

METHODOLOGY

Study design: This was an interventional prospective study

Study area: The study was carried out at a secondary health care facility; General Hospital Ogbomoso. Ogbomoso is located in Ogbomoso south local government area of Oyo State, Nigeria. Malaria is endemic in southwest Nigeria and the HIV prevalence rate is about 5%.

Study participants: Enrolees were confirmed HIV-infected adult Nigerians taking the ritonavir boosted Atazanavir (second line ARV) with medium to high adherence according to modified Morisky adherence scale.⁹ They also had clinical features compatible with malaria and tested +ve for malaria on rapid diagnostic test (FMOH 2001). Other inclusion criteria were provision of individual informed consent and lived within 10 kilometer radius of the study hospital. Patients were excluded if they were less than 18 years of age, had advanced symptomatic HIV infection, had pre-existing heart disease, hypertension, were taking other drugs with similar effects as lumefantrine or atazanavir that may interfere with the result and those who in the judgement of the investigator will not comply with the study protocol. All the female enrolees either had their last menstrual periods within the preceding two weeks of enrolment or were postmenopausal. They all reported not being pregnant.

Procedure: Referral for treatment for malaria was based on malaria symptoms. Such patients were referred for recruitment in the study. History and examination were carried out with a focus to diagnose malaria in prospective enrolees receiving atazanavir/ritonavir. Axillary temperature was taken in each enrolee using a validated digital thermometer.

Each participant had a complete clinical cardiac status assessment with a view to diagnosing pre-existing cardiac disease. The resting pulse rate was taken over 1 minute after subjects have rested for at least 15 minutes. Systolic and diastolic blood pressures were taken with appropriate cuff of a standardized Accoson sphygmomanometer after resting for 15 minutes. Korotkoff phase 1 and V were taken as systolic and diastolic blood pressure respectively. The subject were classified hypertensive if the value was ≥ 140 mmHg systolic or the diastolic blood pressure was ≥ 90 mmHg in an adult recorded at more than two occasions separated by at least fifteen minutes interval.¹⁰ Enrolees were weighed using a digital weighing scale and the weights were recorded in kilograms (Kg) while height was recorded in metres (m). The body mass index (BMI) was subsequently calculated using the following formula:

$$\text{BMI} = \text{weight (kg)} / [\text{height (m)}]^2$$

Malaria diagnosis was based on the result of First response® Malaria Antigen *P. falciparum*, an HRP2-based RDT as recommended by the National malaria treatment guideline (FMOH 2011). First Response rapid card test used was manufactured by Premier medical corporation limited, Kachugam, Nani Daman, (UT) 396 215. INDIA. Each cassette was appropriately labelled with the enrollee's initials, date and study identification number. The test was carried out aseptically according to manufacturer's instruction. The result of the malaria RTD was recorded as positive, negative or indeterminate. Only prospective enrollees that tested positive were enrolled.

A resting standard 12-lead electrocardiogram was obtained in accordance with the recommendations of American Heart Association specifications¹¹ using the Zoncare® Digital three channel ECG machine 1203Q model. The electrodes were applied appropriately on the precordium and limbs with the use of gel to maintain proper contact between the skin and electrodes. Baseline (D0) ECG was carried out before initiation of six dose regimen of AL treatment for malaria. Each dose consisted of four tablets of Lumartem®. Lumartem® is manufactured by Cipla limited, plot 9 & 10, Indore SEZ, pithampur, M.P.-454 775,India. Each tablet of AL contained 20mg artemether and 80 mg of lumefantrine.

The first dose of AL was administered supervised, adequate instruction was given on the dosage and frequency of dosing of subsequent doses. This was done on scheduled time interval and subjects were supervised with regular phone calls and pre-set phone reminder to ensure compliance with medications. They were also monitored for adverse drug reaction.

There were two follow-up visits on days 3 and 7 during which ECG was also done and the tracings were recorded. A structured questionnaire was administered to evaluate clinical progress and detect any adverse drug reaction that might have occurred. ECG tracings were manually read and interpreted by a cardiologist and a senior resident. Parameters evaluated include heart rate, PR interval, QRS duration, QT interval, atrioventricular and intraventricular blocks and other forms of cardiac arrhythmia. The QT interval was corrected for heart rate using the Bazett's formula ($QT_c = \frac{QT}{\sqrt{R-R}}$).¹²

Data Analysis

Data was entered and analysed using the Statistical Package for Social Sciences (SPSS) package Version 20.0 - California, Los Angeles. Continuous data were presented as mean \pm standard deviation and categorical variables were presented as percentages.

Paired T-test was used to assess for significant associations between group means in quantitative variables. Statistical significance was taken as $p < 0.05$, and the confidence level.

RESULTS

The cohort of 71 HIV positive patients taking second line antiretroviral (protease inhibitors) were followed up for six months (between 30th of June 2014 and 26th November 2014)

During this time interval 48 of the 70 who had symptoms compatible with malaria and tested positive for malaria with rapid diagnostic test (RDT) were evaluated for enrolment into the study. Two of the volunteers were excluded. One was hypertensive and another one had abnormal baseline ECG at evaluation (frequent ventricular premature contractions). Only 41 Of the enrolled 46 (89.1%) participants completed the study. Three were lost to follow up before day 7.

The demographics

Of the 41 volunteers that completed the study per protocol, 33 (80.5%) were females while 8 (19.5%) were males. The mean age of the participants is 41.27 years (± 10.14). Singles among the participants are 2.4%, 53.7% were currently married to their first spouse, 19.5% separated, while 7.3% remarried. The average monthly income was 12000 Naira. Further details of socio-demographic characteristics are shown in Table 1.

Table 1: Sociodemographic characteristics of the HIV patients on atazanavir based regimen treated for malaria

Variable	Female (n =33)	Male (n = 8)	Total (41)	Percentage
Age (Years)				
≤ 20	0	0	0	0
21 – 30	3	1	4	9.8
31 – 40	16	3	19	46.3
41 – 50	8	3	11	26.8
51 – 60	4	1	5	12.2
> 60	2	0	2	4.9

Mean ± SD	41.27 ± 10.14			
Marital status				
Single	1	0	1	2.4
Married	18 +3 = 21	4	25	70.0
Widow/Widower	6	1	7	17.1
Divorced	5	3	8	19.5
				7.3
Educational level				
None	6	2	8	19.5
Primary	11	2	13	31.7
Secondary	15	3	18	41.9
Tertiary	1	1	2	4.9
Income (Naira)				
≤ 10,000	25	3	28	68.3
11,000 – 20,000	5	3	8	19.5
21,000 – 30,000	1	2	3	7.3
➤ 30,000	2	0	2	4.9
Body mass index				
Underweight	3	0	3	7.3
Normal	18	3	21	51.2
Overweight	8	5	13	31.7
Obese	4	0	4	9.8

Clinical parameters

The mean axillary temperature on day 0 was $36.58^{\circ}\text{C} \pm 0.76$ with a range of ----- to -----, X number of participants had fever defined as axillary temperature $>37.4^{\circ}\text{C}$. There was no significant difference between the mean temperature on day 0 and those of days 2 and 3 which were $36.65^{\circ}\text{C} \pm 0.35$ and $36.67^{\circ}\text{C} \pm 0.26$ respectively. However, no case of fever was recorded on days 2 and 3.

The mean baseline pulse rate was $83.07 \pm 9.77/\text{min}$ and was not statistically different from that recorded on days 3 and 7 of the study. .

Both systolic and diastolic blood pressure remained with normal limit with no significant change throughout the period.

Table 2: Comparison of some clinical parameters measured before and after artemether-lumefantrine

Variable	Day 0	Day 3	P-value	Day 0	Day 7	P-val	Day 3	Day 7	P-val
PR	83.07 ± 9.77	82.35 ± 13.62	0.581	83.07 ± 9.77	85.78 ± 12.39	0.073	82.35 ± 13.62	85.78 ± 12.39	0.072
SBP	116.04 ± 14.61	117.64 ± 13.29	0.842	116.04 ± 14.61	117.41 ± 14.76	0.926	117.64 ± 13.29	117.41 ± 14.76	0.919
DBP	71.61 ± 10.49	74.70 ± 10.57	0.109	71.61 ± 10.49	72.54 ± 9.80	0.886	74.70 ± 10.57	72.54 ± 9.80	0.133
Temp	36.58 ± 0.76	36.65 ± 0.35	0.581	36.58 ± 0.76	36.67 ± 0.26	0.436	36.65 ± 0.35	36.67 ± 0.26	0.661

PR= Pulse rate

Temp= temperature

SBP= Systolic blood pressure

DBP= Systolic blood pressure

The cardiac electrical activity in HIV-Infected Nigerian adults taking atazanavir/ritonavir

The electrocardiographic parameters before artemether-lumefantrine use reflects the effect of atazanavir on the electrical activity of the heart. The mean heart rate was 77.17 ± 10.21 which is within normal limit.

Though the mean PR interval was 173.19 ± 26.69 which was within normal limit, about 10% had prolonged PR interval. The mean QTc 398.41 ± 27.73 remained within normal limits. None had QTc more than 470ms at baseline.

The cardiac electrical activity during co-administration of artemether-lumefantrine and atazanavir/ritonavir in HIV-Infected Nigerian adults using electrocardiography

There was progressive increase in the mean heart rate from day 0 through day 7 but the mean heart rate were within normal limit on all the days though not statistically significant.

In contrast, there was a progressive decline in the mean PR interval from day 0 through day 3 which was not statistically significant.

There was a statistically significant increase in corrected QT interval (QTc) from day 0 to day 3. Though the value of the mean QTc on day 3 remained within normal limit, 5% (2) of the participant had prolonged QTc.

There was also an observed increase in QTc on day 7 compared to day one which is also statistically significant. There was however a decrease in QTc from day 4 to day 7 which is not statistically significant (table 3).

Table 3: comparison of the electrocardiogram parameters on days 0, 3 and 7

Variable	Day 0	Day 3	P-val	Day 0	Day 7	P-val	Day 3	Day 7	P-val
HR	77.17 ± 10.21	79.04 ± 13.07	0.266	77.17 ± 10.21	86.48 ± 45.74	0.214	79.04 ± 13.07	86.48 ± 45.74	0.287
PR	173.17 ± 26.69	170.24 ± 22.85	0.323	173.17 ± 26.69	165.87 ± 33.71	0.100	170.24 ± 22.85	165.87 ± 33.71	0.270
QTc	398.41 ± 27.73	414.83 ± 34.88	<0.001*	398.41 ± 27.73	411.41 ± 22.63	0.008*	414.83 ± 34.88	411.41 ± 22.63	0.478

*=statistically significant

HR = Heart rate, PR = PR interval, QTc = Corrected QT interval

DISCUSSION

As patients with HIV/AIDS now have longer life expectancy with the antiretroviral therapy, the rates of cardiovascular disease (CVD) are increasing. One of the most feared complications of manifestation of CVD is sudden cardiac death (SCD).¹³ Many of the SCDs occur in patients not previously diagnosed with CVD which makes the high index of suspicion essential in people living with HIV/AIDS. One of the substrate for ventricular fibrillation which is major mechanism of SCD is prolong QTc.

HIV has many effects on the heart and it has been shown to prolong the corrected QT interval, QTc.¹⁴ Likewise, some of the drugs used in the treatment of HIV have been shown to prolong the QTc. Of the antiretroviral drugs (ARVs), protease inhibitors have been demonstrated to block the HERG and therefore prolong the QTc.¹⁵ Indeed there was an FDA alert over effects of ritonavir boosted lopinavir on the heart with warning and precautions regarding QTc interval and PR interval prolongation.¹⁶ Atazanavir which is a new protease inhibitor preferred for its convenient once daily dosing and better side effect profile is not free from this QTc prolongation effect. Indeed cases of Torsades de pointes in patients taking atazanavir have been reported.⁷ This study however shows a QTc within the limit of normal in patients taking ritonavir boosted atazanavir. It is possible that the observed value represent an increase more than that found in HIV negative subjects or ARV naïve HIV positive subjects. The mean PR interval also remain within normal limit but 5% of the study participants showed prolonged PR interval while on ritonavir boosted atazanavir

The finding of prolonged PR and normal QTc is similar to the findings of Busti *et al.*, 2006¹⁷ who studied twenty one patients who were either newly commenced on atazanavir or switched from other drug to atazanavir. ECG was done at baseline, after 2 hours and a month after to evaluate the steady state level on the PR interval, QTc and QTd. A minor but statistically significant increase in PR interval was seen which is not clinically significant.

In this current study, the mean duration on atazanavir was 13 months with a minimum duration of one month and all had medium to high adherence. This ensures steady state evaluation of the effect of the ECG.

The finding in this study is however different from the findings in the study by Gianoti *et al.*, 2007⁸ who observed no significant changes in the PR interval and corrected QT interval (QTc) but found a significant increase in the QRS duration and new asymptomatic bundle

branch blocks. There was however no baseline ECG done in patients in this study before commencement of atazanavir. As documented HIV affects the heart in a number of ways and this observation could be one of the HIV effects on the electrical activity of the heart.

Also the effect could have been of the other drugs the patients were taking. All the patients in this study were taking Zidovudine, tenofovir, and emtricitabine in addition to the ritonavir boosted atazanavir though there is no report of similar effect with these other drugs.

Lumefantrine is an aryl-amino alcohol antimalarial with some structural similarities to halofantrine. It also has physico-chemical characteristics similar to halofantrine by being lipophilic and hydrophobic, with very variable oral bioavailability leading to considerable inter-individual variability in plasma concentrations. However, unlike halofantrine, it proved to have little or no detectable cardiac effects over a wide range of plasma concentrations.^{18,19} Studies have shown conflicting results on the effect of artemether lumefantrine on QTc prolongation. While some studies show no significant increase in the QTc prolongation,¹⁸ other showed a significant increase. There are case reports of artemether lumefantrine causing other cardiac conduction abnormality. Bigeminy was associated with artemether-lumefantrine in a 46 year old man which was corrected after withdrawal of the drug.²⁰

Significant increases in serum concentration have been demonstrated of other drugs when co-administered with atazanavir due to inhibition of various enzymes involved in the metabolism of those drugs. Rosiglitazone and elvitegravir's serum concentration were increased due to the inhibition of CYP2C8 and CYP3A4/UGT1A1 respectively.^{21,22} No study has so far been carried to investigate this effect with artemether or lumefantrine. However, lopinavir/ritonavir was found to increase the serum concentration of lumefantrine.^{23,24}

Also, there are case reports of atazanavir causing prolonged QTc interval and Torsades de pointes especially when administered with other drugs like methadone^{25,26} or macrolide.²⁷

This study found significant increase in the QTc after a standard six-dose artemether-lumefantrine given over a 3 day period in HIV positive patients taking atazanavir based regimen, though this remained well within the limit of normal QT interval. There is an initial rise on the day 3 with slight decline though not down to the baseline. All values were within the normal reference range. This may represent the effect of the theoretical enhanced serum concentration of lumefantrine due to inhibition of its metabolism by Atazanavir, as well as synergistic effect of atazanavir and lumefantrine on QTc prolongation. However, a similar

study using lopinavir rather than atazanavir did not find significant increase in QTc, though this was after a single dose of 80/480mg of artemether-lumefantrine.²⁸

CONCLUSION

High index of suspicion should be maintained in HIV positive patients taking atazanavir when administering other drugs for treating co-morbidities/opportunistic infections as each of these may pose risk for prolong QTc interval and fatal ventricular arrhythmia. Especially when co-administering drugs that could alter the metabolism of atazanavir or whose metabolism is altered by atazanavir and drugs that can also affect the electrical activity of the heart.

REFERENCES

1. WHO. Fact sheet: World Malaria Report 2012. Available: http://www.who.int/malaria/media/world_malaria_report_2012_facts/en/index.html Accessed 22 November 2013
2. World Health Organization (2001) Antimalarial drug combination therapy. Report of a WHO Technical Consultation. (WHO/CDS/RBM/2001.35) WHO Geneva
3. Francesconi P, Fabiani M, Dente M G et al., HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case control study. *AIDS* 2001; vol. 15, no. 18, pp. 2445–2450.
4. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. *Lancet*. 2000 Sep;356(9235):1051-6 [PubMed ID: [11009139](#)]
5. Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. *Lancet*. 2005 Jan;365(9455):233-40 [PubMed ID: [15652606](#)]
6. Havlir DV and O'Marro SD. Atazanavir: new option for treatment of HIV infection. *Clin. Infect. Dis.* [Internet]. 2004 Jun 1 [cited 2013 Dec 28];38(11):1599–604. Available from: <http://cid.oxfordjournals.org/content/38/11/1599.full>
7. Ly T and Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. *Clin. Infect. Dis* 2007; [Internet]. [cited 2013 Dec 26];44(6):e67–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17304444>
8. Gianotti N, Guffanti M, Galli L, Margonato A, Chiaravalli G, Bigoloni A, *et al.*, 2007. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. *AIDS* [Internet]. [cited 2013 Dec 28];21(12):1648–51. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17630564>

9. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self reported measure of medication adherence. *Med Care* 1986;24:67-74.
10. Londe S, Klitzner TS. Auscultatory blood pressure measurement : effect of pressure on the head of the stethoscope. *West J Med* 1984;141:193.
11. American Heart Association Committee Report. Recommendations for standardization of leads and specifications for instruments in electrocardiography and vectorcardiography. *Circulation*1975; 52 : 11–31.
12. Araoye MA. Basic electrocardiography 1st ed. Ilorin, Kwara state Nigeria. Nathadex Publishers 2004. pp 8.
13. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B. Sudden cardiac death in patients with human immunodeficiency virus infection. *J Am Coll Cardiol* 2012.59 (21): 1891-1896
14. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. *J Natl Med Assoc*2005; 97(12): 1657-1661
15. Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD. Blockade of HERG channels by HIV protease inhibitors. *Lancet* 2005. 365(9460):682-686.
16. “FDA Issues Safety Labeling Changes for Kaletra,” FDA Issues Safety Labeling Changes for Kaletra (serial on the Internet). 2009, <http://www.medscape.com>
17. Busti AJ, Tsikouris J P, Peeters MJ, Das SR, Canham RM, Abdullah SM. and Margolis DM. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. *HIV Medicine* 2006; 317–322
18. Van VM., Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, et al. No evidence of cardiotoxicity during antimalarial treatment with Artemether-lumefantrine. *Am. J. Trop. Med. Hyg* 1999; 61(6):964–967
19. Khandave SS, Joshi SS, Sawant SV, Onkar SV. Evaluation of Bioequivalence and Cardio-Hepatic Safety of a Single Dose of Fixed Dose Combination of Artemether and Lumefantrine. *J Bioequiv Availab* 2010. 2: 081-085. doi:10.4172/jbb.1000036
20. Nitin S., Naresh G, Kaustubh M, Shadab S. Artemether-lumefantrine combination causing ventricular bigeminy. *JACM* 2014; 15(3-4): 260-261
21. Servinsky T., Eley T., Tones C., Persson A., Li T. Xu X., Mahnke L., *et al.*, Effect of Atazanavir with or without ritonavir on the pharmacokinetics of the CYP2C8 probe rosiglitazone in healthy subjects. 9th international workshop on pharmacology of HIV Therapy 2008; New Orleans
22. Romanathan S, Wang, Standell T. Pharmacokinetics and drug interaction profile of cobicistat boosted EVG with atazanavir, rousuvastatin or rifabutin. 13th international workshop on pharmacology of HIV Therapy 2012; Barcelona Spain
23. Dooley K. E., Flexner C., Andrade A.S. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited contries . *J infect Dis* 2008;198:948-961
24. German P, Parikh S, Lawrence J, Dorsey G., Rosenthal P. J, Havlir D., *et al.*, Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. *J Acquir Immune Defic Syndr* 2009;51:424–429
25. Bindschedler M, Gilbert L, Degen P, and Sioufi A. Comparison of the cardiac effects of the antimalarials Co-artemether and halofantrine in healthy participants. *Am. J. Trop. Med. Hyg* 2002; 66(3):293–298
26. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. *Am J Cardiol* 2003;15:92(8):995-997. PMID: 14556883

27. Alexander SV, Jan R, Shahram Z. Gerd F. Guido M, Erland E, Michael V.B, and Matthias K. Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection. Case Reports in Medicine. Volume 2010, Article ID 278427
28. Byakika-Kibwika P., Lamorde M., Lwabi P., Nyakoojo W. B., Okaba-Kayom V, Mayanja-Kizza H,*et al.*, Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice 2011;Volume 2011,Article ID 393976,4 pages doi:10.1155/2011/393976

UNDER PEER REVIEW